October 24, 2016 – Invitrocue (ASX:IVQ) announced a collaboration agreement with the Cancer Therapeutics and Stratified Oncology Group at the Genome Institute of Singapore (GIS), A*STAR. Invitrocue and GIS will jointly conduct a pilot feasibility study using Invitrocue’s cell-based 3D scaffolding technology (Onco-PDO™) to culture colorectal cancer organoids.
The aim of the study is to grow and culture colorectal cancer organoids in the laboratory. Once cultured, various drugs will be applied to the colorectal cancer organoids through Invitrocue’s high-throughput screening to ascertain their effectiveness in treating colorectal cancer as a personalised guide to clinical intervention.
“This strategic collaboration agreement in colorectal cancer is another important step in the field of personalised oncology,” said Dr. Steven Fang, Executive Director of Invitrocue. “Oncologists shall be able to assess which drugs will have the greatest benefits for patients before they are administered – a potential game changer in cancer treatment. We are delighted to be working with GIS in this ground breaking research,” he said.
– ENDS –
For more information, please contact:
Matthew Gregorowski, Citadel-MAGNUS
T: +61 2 8234 0100
Invitrocue is a leading healthcare bio-analytic solutions including in vitro cell-based testing technologies and image analytics software for use in digital pathology. Invitrocue has developed a unique 3D cell-based scaffolding technology that mimics human organ samples for using in the field of infectious diseases. In 2016, the company expanded its work in liver disease to the field of oncology. The technology enables patient-derived cancer cells (organoids) to be cultured in laboratories for testing against a panel of drugs to support clinical decision making for individual patients (personalised medicine).
Invitrocue’s technology originated in Singapore’s Agency for Science, Technology and Research (A*STAR). Invitrocue has been developed and validated in partnerships with leading biopharmaceutical companies and scientific collaborators.
Invitrocue currently operates in Singapore and China and is listed on Australian Securities Exchange under the ticker IVQ. Website: www.invitrocue.com
Onco-PDO™, which stands for oncology patient-derived organoid, enables Invitrocue to grow patient-derived tumour cells (an organoid) in its laboratories initially for personalised drug testing using FDA approved drugs to improve individual treatment outcomes in selected solid tumours. Subsequently, Onco-PDO™ may also create a new market for biopharmaceutical companies, medical researchers and academic institutions to understand the impact of cancer treatments prior to conducting time consuming and expensive clinical trials.